Literature DB >> 15826824

Homeostatic niche specification among naïve and activated B cells: a growing role for the BLyS family of receptors and ligands.

Jenni E Crowley1, Laura S Treml, Jason E Stadanlick, Erica Carpenter, Michael P Cancro.   

Abstract

B lymphocyte homeostasis encompasses the establishment and maintenance of independently regulated niches, within which cells compete for viability promoting resources. The BLyS/BLyS receptor family controls the size and composition of these niches, by governing the selection and survival of most peripheral B cells. Moreover, different receptor-ligand sets from this family dominate the regulation of various B cell subsets. These observations suggest a model whereby the regulation of BLyS receptors by differentiative and stimulatory cues yield characteristic BLyS receptor signatures, thus specifying homeostatic niche and competitive advantage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15826824     DOI: 10.1016/j.smim.2005.02.001

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  23 in total

Review 1.  New roles for the BLyS/BAFF family in antigen-experienced B cell niches.

Authors:  Radhika Goenka; Jean L Scholz; Vishal J Sindhava; Michael P Cancro
Journal:  Cytokine Growth Factor Rev       Date:  2014-01-10       Impact factor: 7.638

2.  Aging murine B cells have decreased class switch induced by anti-CD40 or BAFF.

Authors:  Daniela Frasca; Richard L Riley; Bonnie B Blomberg
Journal:  Exp Gerontol       Date:  2006-10-25       Impact factor: 4.032

3.  A role for the B-cell CD74/macrophage migration inhibitory factor pathway in the immunomodulation of systemic lupus erythematosus by a therapeutic tolerogenic peptide.

Authors:  Smadar Lapter; Hava Ben-David; Amir Sharabi; Heidy Zinger; Alona Telerman; Maya Gordin; Lin Leng; Richard Bucala; Idit Shachar; Edna Mozes
Journal:  Immunology       Date:  2010-08-25       Impact factor: 7.397

Review 4.  Non-canonical NF-κB signaling pathway.

Authors:  Shao-Cong Sun
Journal:  Cell Res       Date:  2010-12-21       Impact factor: 25.617

Review 5.  The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity.

Authors:  M P Cancro
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 6.  B-cell-targeted therapies in systemic lupus erythematosus.

Authors:  Vera Sau-Fong Chan; Helen Hoi-Lun Tsang; Rachel Chun-Yee Tam; Liwei Lu; Chak-Sing Lau
Journal:  Cell Mol Immunol       Date:  2013-01-28       Impact factor: 11.530

7.  Human herpesvirus-8 infection leads to expansion of the preimmune/natural effector B cell compartment.

Authors:  Silvia Della Bella; Adriano Taddeo; Elena Colombo; Lucia Brambilla; Monica Bellinvia; Fabrizio Pregliasco; Monica Cappelletti; Maria Luisa Calabrò; Maria Luisa Villa
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

8.  BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.

Authors:  Luis Sanchez-Perez; Bryan D Choi; Elizabeth A Reap; Elias J Sayour; Pamela Norberg; Robert J Schmittling; Gerald E Archer; James E Herndon; Duane A Mitchell; Amy B Heimberger; Darell D Bigner; John H Sampson
Journal:  Cancer Immunol Immunother       Date:  2013-04-17       Impact factor: 6.968

9.  Similarities and differences between selective and nonselective BAFF blockade in murine SLE.

Authors:  Meera Ramanujam; Xiaobo Wang; Weiqing Huang; Zheng Liu; Lena Schiffer; Haiou Tao; Daniel Frank; Jeffrey Rice; Betty Diamond; Karl O A Yu; Steven Porcelli; Anne Davidson
Journal:  J Clin Invest       Date:  2006-02-16       Impact factor: 14.808

10.  CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools.

Authors:  Pradeep Sathyanarayana; Estelle Houde; Deborah Marshall; Amy Volk; Dorie Makropoulos; Christine Emerson; Anamika Pradeep; Peter J Bugelski; Don M Wojchowski
Journal:  Blood       Date:  2009-03-05       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.